2022 World Conference on Lung Cancer (ePosters)-EP08.01-061. A Pilot Study of Avelumab and SABR in Non-Responding and Progressing NSCLC Patients Previously Treated with a Checkpoint Inhibitor

EP08.01-061. A Pilot Study of Avelumab and SABR in Non-Responding and Progressing NSCLC Patients Previously Treated with a Checkpoint Inhibitor

Back to course

Pdf Summary

This pilot study aimed to evaluate the combination of the PD-L1 inhibitor avelumab with stereotactic ablative radiotherapy (SABR) in non-small cell lung cancer (NSCLC) patients who had previously progressed on immune checkpoint inhibitors (ICI). The study enrolled eight patients, six in the progressor cohort and two in the non-responder cohort. Patients underwent SABR in addition to receiving avelumab. The primary objective was to estimate the overall response rate (ORR) in the two cohorts, and secondary endpoints included safety, toxicity, and progression-free survival (PFS).<br /><br />The trial observed one confirmed partial response (PR) in a patient in the progressor cohort, which lasted for 7 months. Two patients in the progressor cohort had stable disease (SD). The ORR for the combined progressor and non-responder cohorts was 12.5%. The median PFS for the entire cohort was 2.75 months.<br /><br />The combination of avelumab and SABR was well-tolerated, with no grade 3 treatment-related toxicity observed. However, the ORR of 12.5% was deemed disappointing, but the small number of enrolled patients limited firm conclusions. Future studies should focus on identifying subsets of patients who may benefit from similar strategies within the current treatment landscape.<br /><br />It is important to note that the trial was closed due to slow accrual and changes in NSCLC treatment options. The study was financially supported by EMD Serono, Inc., and also received support from NIH/NCI grants. The ClinicalTrials.gov identifier for this trial is NCT03158883.

Asset Subtitle

Megan Eileen Daly

Meta Tag

Speaker Megan Eileen Daly

Topic Metastatic Non-small Cell Lung Cancer - Immunotherapy

Keywords

pilot study

avelumab

SABR

NSCLC

immune checkpoint inhibitors

ORR

PFS

partial response

combination therapy

trial closure